

European support for research in the Life Sciences: FP7 and IMI

Alain Deleener - IWT
Co-ordinator European Programmes

EU support for Research and Innovation structure of the presentation

FP7 and IMI

1. FP7: basics, structure and budget
2. FP7: Research for the benefit of SMEs
3. FP7 Rules of participation
4. Innovative Medicines Initiative

FP7 basics

FP7 and IMI

What?

FP7 is the EU **main research funding instrument**. It runs from **2007 to 2013** and has a total **budget of about €54 billion**.

Why?

Objective of FP7: increase the **competitiveness of the European industry** – focus on pre-competitive, problem-oriented („applied“) R&D.

How?


Four main chapters with different focus: **Cooperation, Ideas(ERC), People (Marie Curie) & Capacities**.

Where?

In Europe at large: EU Member States (MS) and Associated Countries (i.e. Switzerland, Norway, Turkey, Israel).

FP7 Structure and Budget

EC Framework Programme is delineated into four Specific Programmes;
total budget of € 50.52 billion



Total FP7 budget, including EURATOM: € 54,582 billion



Cooperation – ‘Tools’

Support will be implemented across all themes through:

Collaborative research
(Collaborative projects; Networks of Excellence; Coordination/support actions)

Joint Technology Initiatives

Coordination of non-Community research programmes
(ERA-NET; ERA-NET+; Article 169)

International Cooperation

Under each theme there will be sufficient flexibility to address both **Emerging needs** and **Unforeseen policy needs**




Collaborative research in FP7: The Cooperation programme

Thematic Priorities

➔	1. Health	6.1
➔	2. Food, agriculture, fisheries and biotechnology	1.9
	3. Information and communication technologies	9.1
	4. Nanosciences, nanotechnologies, materials and new production technologies	3.5
	5. Energy	2.3
	6. Environment (including climate change)	1.9
	7. Transport (including aeronautics)	4.2
	8. Socio-economic sciences and the humanities	0.6
	9. Security & 10. Space	<u>2.8</u>
	Total for collaborative research	€32.4 billion



Health research in FP7



Food, Agriculture and Fisheries, and Biotechnology in the Knowledge Based Bio-Economy (KBBE)

The 3 KBBE Activities in FP7



KBBE - Activity 2.1
Sustainable production and management of biological resources from land, forest and aquatic environments



KBBE - Activity 2.2
'Fork to farm' - Food (including sea-food), health and well being



KBBE - Activity 2.3
Life sciences, biotechnology and biochemistry for sustainable non-food products and processes



SMEs in FP7 Cooperation (themes)

- **research performing SMEs:** can participate in all research actions, in particular those under the research themes of the Cooperation programme (15% target = 4 850 M€)
- identification of areas of particular interest to SMEs in the individual work programmes
- simplified financial and administrative procedures (e.g. 75% funding rate for SMEs, no bank guarantees)



SMEs in FP7

Capacities: research for the benefit of SMEs

FP7 and IMI

Strengthen the innovation capacities of SMEs to develop new products and markets by outsourcing of research:

- increase their research effort
- acquire technological know-how
- extend their networks
- improve the exploitation of research results



10

Research for the benefit of SMEs: target group

FP7 and IMI

- Research for SMEs: supporting small groups of innovative SMEs to solve common or complementary technological problems;
 - **low to medium technology SMEs** with little or no research capability
 - research performing SMEs that need to *outsource* research to complement their core research capability
 - Research for SME associations: supporting SME associations and SME groupings to develop technical solutions to problems common to large numbers of SMEs in specific industrial sectors
 - SME associations representing their members and their common technical problems
- Both schemes will follow a bottom-up approach, no thematic focussing



11

Key Features of the two Schemes


FP7 and IMI

	Research for SMEs	Research for SME associations
Duration	1-2 years	2-3 years
Number of partners	5-10	10-15
Total budget *	€ 0.5 – 1.5 Million	€ 1.5 – 4 Million
Activities	R&D, demonstration, management, other activities.	R&D, demonstration, management, other activities.



12

FP7: from call to project



Who can participate?

- FP7 and IMI
- Any undertaking, university or research centre or other legal entity, whether established in a:
 - Member State (MS)
 - Associated country (Ac) , or
 - third country
 - International organisations and participants from third countries can participate only if in addition to the minima

Conditions for participation

- FP7 and IMI
- **Minimum condition**, general rule, at least 3 independent participants from 3 different MS or Ac
 - **Additional conditions** can be established by the SP or WP (number or type of participant, place of establishment)
 - **Specific conditions** may also apply for:
 - Frontier research actions, at least 1 legal entity established in a MS or Ac
 - Collaborative projects addressing the participation of International Cooperation Partner Countries (ICPC) minimum is 4 participants, 2 of which from MS or Ac and another 2 from ICPC countries unless otherwise foreseen in the WP

Evaluation & submission procedures

FP7 and IMI

- Evaluations may follow a single or a two-step *evaluation* procedure or two-stage *submission* procedure
- *Two-step evaluation procedure*, only proposals that pass the 1st step, based on the evaluation against a limited set of criteria, will go forward for further evaluation
- *Two-stage submission procedure*, only applicants whose proposals pass the evaluation for the 1st stage will be requested to submit a complete proposal in the 2nd stage



16

Criteria for evaluation

FP7 and IMI

- The Commission will evaluate the proposals submitted according to the following **main criteria**:
 - Scientific and/or technological **excellence**
 - **relevance** to the topic of the call
 - quality and efficiency of the **implementation and management**
 - **potential impact** of project results
- **Additional requirements** on the application of these criteria may be added in the work programmes



17

Eligibility for funding

FP7 and IMI

- Legal entities from MS and Ac or created under Community law and the JRC
- International European interest organisations
- Legal entities established in international cooperation partner countries (ICPC), and
- International organisations and legal entities from third countries other than ICPC only if:
 - provided for in SP or WP; or
 - their contribution is essential for carrying out action; or
 - provision for funding is provided for in a bilateral agreement between Community and the third country



18

Upper funding limits

FP7 and IMI

Reimbursement will be according to the type of action and/or activity

- **Research and technological development activities:** up to **50%** of eligible costs, or up to **75%** for:
 - Non profit public bodies
 - secondary and higher education establishments
 - research organisations
 - SMEs
 - Security related research, for highly reliable capabilities with impact on security of European citizens and targeted to a limited number of public users
- **Demonstration activities:** up to **50%**
- **Other activities** including management: up to **100%**
- **Actions that will be reimbursed up to 100%:**
 - Frontier research
 - Coordination and support
 - Training and career development of researchers



19

Reimbursement of eligible costs

FP7 and IMI

- Most funding schemes use reimbursement of **eligible costs**
 - **Eligible**
 - actual (average personnel costs may be used if do not differ significantly from actual)
 - incurred during duration of project
 - in accordance with the beneficiary usual accounting and management principles
 - recorded in the accounts of beneficiary
 - used for the sole purpose of achieving the objectives of the project
 - **Non-eligible** (identifiable indirect taxes including VAT...)



20

Indirect Cost

FP7 and IMI

- Participants may charge eligible **direct** and **indirect** costs
- **Reimbursement of indirect costs :**
 - **For all:**
 - either actual overhead, or simplified method, or
 - flat rate of **20%** of direct costs
 - **For Non profit Public Bodies, Secondary and Higher Education establishments, Research Organisations, and SMEs** unable to identify real indirect costs, may apply for a flat rate of **60%** for funding schemes with Research, Technological Development & Demonstration
 - **For Coordination and Support Actions** limit of
 - **7%** of direct costs



21

Key factors for success in applying for FP7 funding

FP7 and IMI

Competition is tough: only the best projects get funded

- The proposal must be in scope with the topic and the work programme (not wishful thinking)
- The consortium of partners must be excellent and appropriate for the task (select the right partners)
- The proposal must address all 3 criteria
- Convince the evaluators (don't rely on reputation)
- and, of course, respect the basic rules (deadlines, n° participants, ceilings, length, ethics, ...)



Information and assistance for FP7 a.o

FP7 and IMI

more information on

- workprogrammes and calls themes
- rules of participation
- (partnering) events and informations days
- partner searches

www.europrogs.be

assistance

- programme/theme orientation
- helpdesk for administrative, financial and legal issues
- proofreading proposals

Training seminar: 15 december 2009



Innovative Medicines Initiative a public-private partnership

FP7 and IMI



Innovative Medicines Initiative (IMI) Joint Technology Initiative


FP7 and IMI

- Public-private partnership between industry (more in particular pharmaceutical industry) and public sector (EC)
- **Aim:** to remove major bottlenecks in drug development, acting where research is the key
- **Long term objectives:** to increase competitiveness of European pharmaceutical sector and foster EU as most attractive place for pharmaceutical R&d, thereby enhancing access to innovative medicines for patients
- **Top-down approach:** topics defined by industry together with EC and Scientific Advisory Board
- Private consortia (EFPIA, Coordinator) + public/applicant consortia



The Strategic Research Agenda focuses on bottlenecks in biomedical R&D


FP7 and IMI



IMI Call process



IMI Projects - Funding principles



IMI JU contributes with funding up to:

- 75% of total eligible RTD costs
- 100% of total eligible management and training costs
- Note that total eligible costs include direct eligible costs + 20% to cover overhead

IMI JU contributes:

- 0% of any costs
- EFPIA companies provide in-kind contributions \geq IMI JU funding



IMI Call Process 2009

FP7 and IMI

- Topics included in 2009 call available at www.imi.europa.eu from today
- The call is foreseen to open 30 October 2009 with deadline 29 January 2010.
- Call documents: Application forms, Rules for participation and Rules for submission, evaluation and selection will be available at www.imi.europa.eu in connection with the launch.
- Information day 2nd call: 17 November 2009 (Brussels Expo)



Instituut voor de Aanmoediging van Innovatie
door Wetenschap en Technologie in Vlaanderen

IWT - europrogs
Bischoffsheimlaan 25
B-1000 Brussel
Tel.: +32 (0)2 788 15 67
Fax.: +32 (0)2 223 11 81
E-mail: europrogs@iwt.be
www.europrogs.be